Joshua Alpert, MD
Orthopaedic Surgery · Elgin, ILNPI 1225121528
Payments from drug & device makers
Across 85 payments — averaging $26.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pacira Pharmaceuticals Incorporated$263
- Electronic Waveform Lab, Inc.$211
- Fidia Pharma USA Inc.$205
- Orthofix Medical, Inc.$196
- Vericel Corporation$171
- Amgen$171
- plus $1K from 20 others
What the payments were for
- Food & beverage$2,229100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pacira Pharmaceuticals Incorporated | 9 | $263 |
| Electronic Waveform Lab, Inc. | 1 | $211 |
| Fidia Pharma USA Inc. | 11 | $205 |
| Orthofix Medical, Inc. | 6 | $196 |
| Vericel Corporation | 6 | $171 |
| Amgen | 11 | $171 |
| Catalyst Orthoscience | 3 | $160 |
| Pacira Therapeutics, Inc. | 7 | $147 |
| Johnson & Johnson | 3 | $125 |
| Dynasplint Systems Inc. | 1 | $84 |
| Stryker | 3 | $79 |
| Sanofi-aventis U.S. LLC | 5 | $68 |
| Vertex | 3 | $59 |
| Smith+Nephew | 2 | $57 |
| ERMI LLC | 2 | $32 |
| Kowa Pharmaceuticals America, Inc. | 2 | $29 |
| Novo Nordisk | 1 | $23 |
| Medtronic | 1 | $21 |
| Ultragenyx Pharmaceutical Inc. | 1 | $21 |
| Davol Inc. | 1 | $20 |
| Sonex Health, Inc. | 1 | $19 |
| Boston Scientific | 1 | $17 |
| Kinex Medical Company LLC | 1 | $14 |
| Currax Pharmaceuticals LLC | 1 | $14 |
| Terumo BCT, Inc. | 1 | $13 |
| Hikma Pharmaceuticals USA | 1 | $12 |
How this compares
$2,229 in reported general payments places this provider in the 40th percentile of 844 orthopaedic surgery providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Meloxicam | 289 | $1,127 |
| Celecoxib | 12 | $460 |
| Methylprednisolone | 48 | $287 |
| Tramadol Hcl | 22 | $90 |
| Cyclobenzaprine Hcl | 12 | $83 |
Paid to pharmacies, not to this prescriber.
Other orthopaedic surgery in Elgin
- Peter BonuttiEffingham$24.3M
- Steven HaddadGlenview$12.6M
- Aaron RosenbergChicago$12.4M
- Treg BrownHerrin$6.6M
- Kamal IbrahimOakbrook Terrace$4.9M
- Wayne GoldsteinMorton Grove$4.9M
- Steven MatherDowners Grove$4.3M
- Steven MardjetkoMorton Grove$4.3M
- Steven ChudikWestmont$4.1M
- Matthew SquireAurora$2.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.